A Mission to Foster Cardiovascular Research
The Cardiovascular Research Institute of Vermont (CVRI-VT) exists to foster cardiovascular research at The University of Vermont. As an organization, it is broadly inclusive of investigators at the University of Vermont who are pursuing cardiovascular research and includes and serves members of multiple departments.
Our key objectives are to:
- improve communication, particularly across disciplines, departments, and colleges;
- increase collaboration;
- increase funding to support cardiovascular research; and
- advance and highlight excellence in research nationally and internationally.
» Join our mailing list to receive announcement and updates.
» Read the Vermont Biz article about our April 2014 re-launch event.
Dr. Schneider's lab is working to elucidate factors that modulate platelet function, to associate platelet function with cardiovascular events, and to evaluate the impact of therapeutic agents on platelet function.
Above, Dr. Schneider has added a sample of whole blood to a tube containing platelet-identifying antibodies and activation-specific antiplatelet markers, and he is now gently flicking the bottom of the tube to mix the contents. The tube will then rest for 15 minutes at room temperature before the contents are fixed, diluted, and analyzed in the flow cytometer to assess the level of platelet activation.
The Cipolla lab studies the cerebral circulation under physiological and pathological conditions— particularly how changes in cerebrovascular structure and function affect cerebral blood flow regulation and hemodynamics in ways that could promote brain injury.
Here, senior technician Julie Sweet has just removed a rat brain after it was exposed to ischemic stroke. The cerebral arteries will be dissected from the stroked side of the brain for isolation and study of their contractile properties.
Click here to learn more about the work being done in Dr. Cipolla’s lab.
The Warshaw lab studies how myosin-binding protein C (MyBP-C) (red/ yellow structure) modulates the heart’s contraction. With mutations to the MyBP-C gene linked to sudden death in young athletes, the Warshaw Lab is working to unravel how MyBP-C interacts with myosin, the heart’s tiny molecular motor, to tune cardiac performance on a beat-to-beat basis.
Last modified June 02 2014 09:34 AM